Risedronate in the Prevention of Osteoporosis in Postmenopausal Women
Status:
Completed
Trial end date:
2004-06-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To demonstrate that risedronate 35-mg once weekly is more efficacious than placebo in
increasing or maintaining bone mineral density (BMD) of the lumbar spine after 1 year of
treatment in women who are non-osteoporotic and 0.5-5 years postmenopausal.
Secondary objectives:
- To demonstrate that risedronate 35-mg once weekly is more efficacious than placebo in
increasing or maintaining total proximal femur, femoral neck, and trochanter BMD after 1
year of treatment in women who are 0.5-5 years postmenopausal
- To assess the general safety of 35-mg risedronate administered once weekly.